Oral Answers to Questions

Charlie Maynard Excerpts

Tuesday 25th March 2025 Commons Chamber

[Ashley Dalton]

My hon. Friend is right: coastal communities face unique challenges when it comes to health inequalities. I will shortly attend the all-party group for coastal communities, where I will meet him and colleagues to discuss these issues.

[Charlie Maynard (Witney) (LD)]

As the Secretary of State will know, in 2018, this House allocated £40 million of funding in memory of Dame Tessa Jowell, who was killed by a brain tumour. Seven years on, less than half of that money has been spent. The money is doing no good sitting in a bank, so will the Secretary of State please commit to spending that money within a decade of Dame Tessa’s death?

[Wes Streeting]

I am grateful to the hon. Gentleman for his question, as it gives me the chance to pay tribute to the late great Baroness Jowell, as well as to the work taking place in her name through the Tessa Jowell Brain Cancer Mission. There have been frustrating delays in getting funding out the door for the purpose for which it is intended. Ministers are looking carefully at this issue, and we want to make more progress more quickly, to ensure that families do not receive the same death sentence that our late friend did.

Rare Cancers Bill

Charlie Maynard Excerpts

2nd reading
Friday 14th March 2025 Commons Chamber

[Charlie Maynard (Witney) (LD)]

I thank the hon. Members for Edinburgh South West (Dr Arthur), for Mitcham and Morden (Dame Siobhain McDonagh) and for Birmingham Erdington (Paulette Hamilton), because I have enjoyed working with them on the Bill. We all have our own stories. I should state my personal interest. My sister Georgie is sitting in the Gallery. She was diagnosed with a GBM—glioblastoma multiforme—nearly two years ago. I would like to say that she is alive and well, but let me just say that she is alive and she is doing well. She has been brave, determined and an inspiration to us all. It is particularly painful as she is a mother of three, a wife, a daughter and a sister. We have a lot to focus on, and it is on us collectively.

I will not rehash too much, and I will try to resist having a cry-fest, but it might be difficult. Our actions, and what we do as a team, are what we will be judged on. I am going to throw it over to the Labour side a little, because they are in government now and they have more power than we do in opposition. When we leave the Chamber today, I ask each Government MP to ask, “Okay, what are we actually going to do?” The talk in this Chamber is nice, but it is the actions that count.

I will pick up on two points. The first is the trial register. We have first-hand experience with Georgie of trying to find what trials are out there. Obviously, there are not enough trials; we know that, and that is something we need to fix. Also, matching patients with trials is not rocket science—that is a basic thing. I would also encourage the Government, rather than just starting from scratch and taking months to reinvent the wheel, to find out what is going on in the private sector and what trials and registers of people seeking trials are already out there, and to build on that. If there is a partnership with some company, that is fine, but let us move quickly, because speed really counts.

The second point is about orphan drug regulations. A key trigger for me getting into politics was Brexit. I thought it was a disastrous idea, and I still do. I struggle to find any possible gains from Brexit, but there is one thing that we could do. The EU has regulations on orphan drugs; ours could be more generous. We could pull research into the UK by giving patents for a few extra years, which would encourage people to dig into the research in these critical areas. I live in hope of that one potential gain.

Even if products are obtained, reimbursement has to be accessible on the NHS, which is far from certain. Ensuring that there is a robust, timely and accessible route to making these drugs available on the NHS for patients really counts. It is critical that that does not fall off the radar. Also, we are really falling behind in the number of clinical researchers active in the UK today. If we want to get this research moving, we must think about what we are doing to get clinical researchers working hard in this space and in others, because we are not doing a good enough job on that.

That is all I will say. Let me just return to my first point: we need action. It is good to have those in the Gallery here today.

Oral Answers to Questions

Charlie Maynard Excerpts

Tuesday 19th November 2024 Commons Chamber

[Stephen Kinnock]

We have pledged to bring back the family doctor, and we have already invested an additional £82 million in the additional roles reimbursement scheme to recruit 1,000 more newly qualified GPs in 2024-25. We are also committed to fixing the front door of the NHS, for example through £100 million of capital funding that was announced in the Budget. We are fully aware of the pressures, and we will set out further details on funding allocations for next year in due course.

[Charlie Maynard (Witney) (LD)]

T5. Will the Secretary of State give a clear date by which QR codes will be incorporated into the NHS app at the point of care, thereby making the process faster and safer, as was highlighted to me by Dr Steve Bright at the Windrush health centre in Witney?

[Wes Streeting]

I might resist the invitation to give a specific date today, but the hon. Gentleman makes a valuable point about the ease of use of the NHS app, and I will write to him further on that point.